These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15090802)

  • 1. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong JN; Soriano V; Heneine W; Zeh C; Agwale SM; Wambebe C; Odama L; Wiktor SZ
    AIDS; 2004 Feb; 18(3):495-502. PubMed ID: 15090802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
    Colson P; Henry M; Tourres C; Lozachmeur D; Gallais H; Gastaut JA; Moreau J; Tamalet C
    J Clin Microbiol; 2004 Feb; 42(2):570-7. PubMed ID: 14766818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
    AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.
    Fonjungo PN; Mpoudi EN; Torimiro JN; Alemnji GA; Eno LT; Lyonga EJ; Nkengasong JN; Lal RB; Rayfield M; Kalish ML; Folks TM; Pieniazek D
    J Clin Microbiol; 2002 Mar; 40(3):837-45. PubMed ID: 11880402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of drug resistance-related polymorphisms in treatment-naive individuals infected with nonsubtype B HIV type 1 in Cameroon.
    Youngpairoj AS; Alemnji GA; Eno LT; Lyonga EJ; Eloundou MA; Shanmugam V; Mpoudi EN; Folks TM; Kalish ML; Pieniazek D; Fonjungo PN
    AIDS Res Hum Retroviruses; 2012 Jul; 28(7):675-84. PubMed ID: 21923557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic diversity of human immunodeficiency virus-1 isolates in Paraná, Brazil.
    Toledo PV; Carvalho DS; Rossi SG; Brindeiro R; de Queiroz-Telles F
    Braz J Infect Dis; 2010; 14(3):230-6. PubMed ID: 20835505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China.
    Zhong P; Kang L; Pan Q; Konings F; Burda S; Ma L; Xue Y; Zheng X; Jin Z; Nyambi P
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):91-101. PubMed ID: 14501800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
    Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL
    J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
    Dumans AT; Barreto CC; Santos AF; Arruda M; Sousa TM; Machado ES; Sabino EC; Brindeiro RM; Tanuri A; Duarte AJ; Soares MA
    Infect Genet Evol; 2009 Jan; 9(1):62-70. PubMed ID: 18992847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturally occurring sequence polymorphisms within HIV type 1 group O protease.
    Luk KC; Kaptué L; Zekeng L; Soriano V; Gürtler L; Devare SG; Schochetman G; Hackett J
    AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1555-61. PubMed ID: 11709100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference.
    Han X; Zhang M; Dai D; Wang Y; Zhang Z; Liu J; Geng W; Jiang Y; Takebe Y; Shang H
    AIDS Res Hum Retroviruses; 2007 Mar; 23(3):357-64. PubMed ID: 17411368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.
    Vidal JE; Freitas AC; Song AT; Campos SV; Dalben M; Hernandez AV
    Braz J Infect Dis; 2011; 15(3):245-8. PubMed ID: 21670925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naïve Sequences.
    Ledwaba J; Sayed Y; Pillay V; Morris L; Hunt G
    AIDS Res Hum Retroviruses; 2019 Jul; 35(7):673-678. PubMed ID: 30793914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
    Capel E; Martrus G; Parera M; Clotet B; Martínez MA
    J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.